Biotech Values

[rfj1862]

>If Provenge gets the nod--DNDN could quadruple to $16 based on a 4 times projected sales of $500 million in the first year.

If it is rejected--I take a 50% hit and have to wait another 18 months or so for the other 500 patient trial they are doing to be completed.<

The problem with your calculated gamble is that this is exactly the same calculated gamble that every hedge fund, individual investor, their parents, grandparents, and colleagues are taking with DNDN.

I'm guessing the potential upside is much, much smaller--a buck or two--and the downside might be greater.

Doing the same thing as everyone else is never a great way to make money. Just my opinion, of course.